CTRI/2019/11/021974Active, not recruitingPhase 2
A Phase II open-label, single-arm, multi-center study ofruxolitinib added to corticosteroids in pediatric subjectswith moderate and severe chronic graft vs. host diseaseafter allogeneic stem cell transplantation
ovartis Healthcare Pvt Ltd0 sites0 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Subjects who have undergone alloSCT from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood. Recipients of myeloablative or reduced intensity conditioning are eligible.
- •Subjects with diagnosed moderate to severe cGvHD according to NIH 2014 Consensus Criteria (Section 16.2) prior to Cycle 1 Day 1. Other possible diagnoses for clinical symptoms supporting cGvHD diagnoses must be excluded (e.g., infection, drug side effects, malignancy). Subjects must be either:
- •Treatment-naive cGvHD subjects that have not received any prior systemic treatment for cGvHD except for a maximum 72h of prior systemic corticosteroid therapy of methylprednisolone or equivalent after the onset of chronic GvHD. Subjects are allowed to have received prior systemic treatment for cGvHD prophylaxis (as long as the prophylaxis was started prior to the diagnosis of cGvHD).
- •OR Steroid-refractory moderate to severe cGvHD as per institutional criteria, and still receiving systemic corticosteroids for the treatment of cGvHD for a duration of <18 months prior to Cycle 1 Day 1.
Exclusion Criteria
- •Subjects who initiated systemic calcineurin inhibitors (CNI; cyclosporine or tacrolimus) within 3 weeks prior to start of ruxolitinib on Cycle 1 Day 1. Note: systemic CNI are allowed when initiated > 3 weeks from start of ruxolitinib.
- •Failed prior alloSCT within the past 6 months
- •Significant respiratory disease including subjects who are on mechanical ventilation or who have a resting oxygen saturation < 90% by pulse-oximetry on room-air.
- •Impairment of gastrointestinal (GI) function (unrelated to GvHD) or GI disease (unrelated to GvHD) that may significantly alter the absorption of oral ruxolitinib (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection),
- •Cholestatic disorders, or unresolved sinusoidal obstructive syndrome/veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to cGvHD and ongoing organ dysfunction)
- •Presence of clinically active uncontrolled infection including significant bacterial, fungal, viral or parasitic infection requiring treatment.
- •Known human immunodeficiency virus (HIV) infection.
- •Evidence of uncontrolled hepatitis B virus (HBV) or hepatitis C virus (HCV) based on assessment done by Investigator or delegate.
- •Known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.
- •History of bone disorders such as osteogenesis imperfecta, rickets, renal osteodystrophy, osteomyelitis, osteopenia, fibrous dysplasia, osteomalacia etc. prior to the underlying diagnosis which resulted in the alloSCT.
- •History of endocrine or kidney related growth retardation prior to the underlying diagnosis which resulted in the alloSCT.
- •Evidence of clinically active tuberculosis (clinical diagnosis per local practice)
Investigators
Similar Trials
Active, not recruiting
Phase 1
Activity, safety and pharmacokinetics in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantchronic graft versus host diseaseMedDRA version: 20.0Level: LLTClassification code 10064677Term: Graft versus host disease in intestineSystem Organ Class: 100000004870MedDRA version: 20.0Level: LLTClassification code 10075161Term: Graft versus host disease in GI tractSystem Organ Class: 100000004870EUCTR2018-003296-35-LTovartis Pharma AG42
Active, not recruiting
Phase 1
Activity, safety and pharmacokinetics in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantEUCTR2018-003296-35-SKovartis Pharma AG42
Active, not recruiting
Phase 1
Activity, safety and pharmacokinetics in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantchronic graft versus host diseaseMedDRA version: 20.0Level: LLTClassification code 10064677Term: Graft versus host disease in intestineSystem Organ Class: 100000004870MedDRA version: 20.0Level: LLTClassification code 10075161Term: Graft versus host disease in GI tractSystem Organ Class: 100000004870EUCTR2018-003296-35-ITovartis Pharma AG42
Active, not recruiting
Phase 1
Activity, safety and pharmacokinetics in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantchronic graft versus host diseaseMedDRA version: 20.0 Level: LLT Classification code 10064677 Term: Graft versus host disease in intestine System Organ Class: 100000004870MedDRA version: 20.0 Level: LLT Classification code 10075161 Term: Graft versus host disease in GI tract System Organ Class: 100000004870EUCTR2018-003296-35-CZovartis Pharma AG42
Active, not recruiting
Phase 1
Activity, safety and pharmacokinetics in pediatric subjects with moderate and severe chronic graft vs. host disease after allogeneic stem cell transplantchronic graft versus host diseaseMedDRA version: 20.0Level: LLTClassification code 10064677Term: Graft versus host disease in intestineSystem Organ Class: 100000004870MedDRA version: 20.0Level: LLTClassification code 10075161Term: Graft versus host disease in GI tractSystem Organ Class: 100000004870EUCTR2018-003296-35-SIovartis Pharma AG42